Clinical trials
Diabetes Mellitus, Type 2 trials in New Zealand
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
76 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 8 |
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 4 |
| 2010 | 10 |
| 2011 | 3 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 58 |
| Terminated | 8 |
| Active, not recruiting | 4 |
| Recruiting | 4 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 14 |
| Takeda | 12 |
| GlaxoSmithKline | 7 |
| Janssen Research & Development, LLC | 6 |
| Eli Lilly and Company | 4 |
| Hoffmann-La Roche | 4 |
| AstraZeneca | 3 |
| Lexicon Pharmaceuticals | 3 |
| Bayer | 2 |
| DiObex | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 76 |
| Diabetes Mellitus | 18 |
| Obesity | 8 |
| Glucose Metabolism Disorders | 7 |
| Cardiovascular Diseases | 6 |
| Dyslipidemias | 6 |
| Diabetic Nephropathies | 5 |
| Renal Insufficiency, Chronic | 5 |
| Hyperglycemia | 3 |
| Kidney Diseases | 3 |
Trials
Showing 1 to 25 of 76. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.